The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT04634500
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 200 participants
- Registry
-
NCT04634500
-
- Other papers using this trial's data
- Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04634500. Randomized; double masking; primary purpose treatment. Start 2020-11-18 (actual); primary completion 2021-11-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.
- Acronym
- ENHANCE-M
- Condition
- T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug)
- Dapagliflozin
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
Record details
- Record id
cardio:ct-nct04634500- Content hash
be59cb315e2d4a5987b472f4ad5248290f60d487c1a07a8fb76864f24ca8f056